Moderna (MRNA) PT Lowered to $108 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $228.44 --0%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
UBS analyst Eliana Merle lowered the price target on Moderna (NASDAQ: MRNA) to $108.00 (from $140.00) while maintaining a Buy rating.
You May Also Be Interested In
- Moderna (MRNA) call put ratio 1 call to 1.1 puts into quarter results
- Marico Ltd (MRCO:IN) PT Raised to INR1,020 at Nomura/Instinet
- Yum China Holdings, Inc (9987:HK) (YUMC) PT Lowered to HK$445 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
